Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06PAZ
|
|||
| Former ID |
DAP000519
|
|||
| Drug Name |
Encainide
|
|||
| Synonyms |
Encainida; Encainidum; Enkaid; Encainida [Spanish]; Encainide [French]; Encainidum [Latin]; No stereochem; MJ 9067; Encainide (INN); Encainide [INN:BAN]; MJ-9067; MJ-9067-1; Encainide Hydrochloride, (+-)-Isomer; (+-)-2'-[2-(1-methyl-2-piperidyl)ethyl]-p-anisanilide; (+-)-4-Methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide; (+/-)-4-Methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide; 4-methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide; 4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide; 4-methoxy-N-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Heart arrhythmia [ICD-11: BC65; ICD-10: I49, I49.8] | Withdrawn from market | [1], [2] | |
| Therapeutic Class |
Antiarrhythmic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H28N2O2
|
|||
| Canonical SMILES |
CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC
|
|||
| InChI |
1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)
|
|||
| InChIKey |
PJWPNDMDCLXCOM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 66778-36-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9192, 6165533, 7979158, 8180518, 12012630, 15373859, 34712961, 46504470, 48415942, 49877070, 50064743, 57313176, 80562377, 96024590, 99313642, 104354474, 117563414, 124896651, 125749069, 126666719, 128926702, 134223157, 134337811, 135007178, 135049140, 137231478, 142970991, 162518740, 163693531, 163852995, 172892145, 179225703, 184536609, 184547004, 194147897, 196396473, 203084558, 223669045, 224787244, 225384108, 226471947, 241066723, 249965307, 252345471
|
|||
| ChEBI ID |
CHEBI:4788
|
|||
| ADReCS Drug ID | BADD_D00769 | |||
| SuperDrug ATC ID |
C01BC08
|
|||
| SuperDrug CAS ID |
cas=066778367
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel alpha Nav1.5 (SCN5A) | Target Info | Blocker | [3] |
| KEGG Pathway | Adrenergic signaling in cardiomyocytes | |||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Cardiac Progenitor Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. Mayo Clin Proc. 1987 Nov;62(11):1033-50. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.